[10], MSM aged 46 or older accounted for approximately 10% of the sample ( N = 4003) and 5% of seroconverting participants as based on biospecimen testing completed at each 6 month assessment period. In the later examination by Ostrow et al. [9], MSM over the age of 46 accounted for a larger portion of the sample (N = 1667), making up 47% of the total sample and 27% of the men who seroconverted in the follow-up period. Analyses were not conducted separately for older MSM, with overall findings from both studies indicating that that increasing age was actually a protective factor against seroconversion. In Plankey et al.